SequelSEC

Amneal Pharmaceuticals, Inc. AMRX

Pharmaceutical Preparations · CIK 0001723128 · Fiscal year ends 1231

AnnualQuarterlyTTM
Revenue
$3.12B
Fiscal year ended 2026-06-30
Operating income
$453.92M
Fiscal year ended 2026-06-30
Free cash flow
$127.84M
Fiscal year ended 2026-06-30

Amneal Pharmaceuticals, Inc. (AMRX) reported revenue of $3.12B and net income of $157.36M for the fiscal year ended 2026-06-30. This page shows 1 annual period of income statement, balance sheet and cash flow figures normalized from Amneal Pharmaceuticals, Inc.’s SEC filings, each linked to the filing it came from. It is classified by the SEC under Pharmaceutical Preparations.

Income

Amneal Pharmaceuticals, Inc. income by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-30
Revenue$3.12B
Cost of revenue$1.89B
Gross profit$1.23B
Operating income$453.92M
Net income$157.36M
Research & development$175.57M
Weighted-average diluted sharesUnavailable
Pretax income$201.18M
Income tax expense-$14.14M
Diluted EPSUnavailable
Selling, general & administrative$571.86M
General & administrativeUnavailable
Selling & marketingUnavailable

Balance

Amneal Pharmaceuticals, Inc. balance by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-30
Cash & equivalents$127.64M
Total assets$3.78B
Current assets$1.95B
Total liabilitiesUnavailable
Current liabilities$883.19M
Total equity incl. NCI$33.02M
Temporary (mezzanine) equity$83.96M
Inventory$677.95M
Accounts receivableUnavailable
Goodwill$593.50M
Long-term debt$2.56B
Accounts payableUnavailable

Cash flow

Amneal Pharmaceuticals, Inc. cash flow by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-30
Operating cash flow$200.78M
Capital expenditures$72.94M
Investing cash flow-$212.37M
Financing cash flow$69.63M
Net change in cash$55.95M
Stock-based compensation$35.63M
Common dividends paidUnavailable
Common share repurchasesUnavailable
Depreciation & amortizationUnavailable

Derived

Amneal Pharmaceuticals, Inc. derived by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-30
Free cash flow$127.84M
Gross margin39.3%
Operating margin14.6%
FCF margin4.1%
SBC / revenue1.1%
Current ratio2.20x
Revenue YoY growth9.3%
Net margin5.0%
R&D / revenue5.6%
CapEx / revenue2.3%
Long-term debt / equity77.65x
Effective tax rate-7.0%

Amounts are abbreviated; the exact reported value is carried in each cell. — means unavailable, not zero. Open AMRX in the interactive workspace to inspect any figure back to its filing.

Source filings

10-Q · Filed 2026-08-06View SEC filing
10-Q · Filed 2026-05-07View SEC filing
10-K · Filed 2026-02-27View SEC filing
10-Q · Filed 2025-11-06View SEC filing
10-Q · Filed 2025-08-07View SEC filing
10-Q · Filed 2025-05-07View SEC filing

Companies in the same industry

AAGH AARD ABBV ABCL ABEO ABT ABUS ABVC ACAD ACET ACRS ACRV

Every accounting identity this site checks — the balance sheet, the gross profit bridge and the cash flow statement — reconciles in every period shown.